Citigroup’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-280,324
| Closed | -$15.4M | – | 6692 |
|
|
2022
Q2 | $15.4M | Buy |
280,324
+262,834
| +1,503% | +$13.8M | 0.01% | 927 |
|
|
2022
Q1 | $561K | Buy |
17,490
+10,146
| +138% | +$291K | ﹤0.01% | 3433 |
|
|
2021
Q4 | $160K | Buy |
+7,344
| New | +$162K | ﹤0.01% | 4477 |
|
|
2020
Q4 | – | Sell |
-36
| Closed | – | – | 7717 |
|
|
2020
Q3 | $0 | Hold |
36
| – | – | ﹤0.01% | 7676 |
|
|
2020
Q2 | $0 | Hold |
36
| – | – | ﹤0.01% | 7755 |
|
|
2020
Q1 | $0 | Sell |
36
-1
| -3% | -$13 | ﹤0.01% | 7850 |
|
|
2019
Q4 | $0 | Hold |
37
| – | – | ﹤0.01% | 7875 |
|
|
2019
Q3 | $1K | Hold |
37
| – | – | ﹤0.01% | 7649 |
|
|
2019
Q2 | $1K | Hold |
37
| – | – | ﹤0.01% | 7705 |
|
|
2019
Q1 | $3K | Hold |
37
| – | – | ﹤0.01% | 7506 |
|
|
2018
Q4 | $2K | Hold |
37
| – | – | ﹤0.01% | 7531 |
|
|
2018
Q3 | $2K | Hold |
37
| – | – | ﹤0.01% | 7631 |
|
|
2018
Q2 | $4K | Buy |
+37
| New | +$3.71K | ﹤0.01% | 7399 |
|
|
2017
Q1 | – | Sell |
-3
| Closed | – | – | 7401 |
|
|
2016
Q4 | $0 | Sell |
3
-119
| -98% | -$7.42K | ﹤0.01% | 7381 |
|
|
2016
Q3 | $9K | Buy |
122
+20
| +20% | +$1.55K | ﹤0.01% | 6594 |
|
|
2016
Q2 | $8K | Sell |
102
-4
| -4% | -$762 | ﹤0.01% | 6657 |
|
|
2016
Q1 | $29K | Sell |
106
-20
| -16% | -$6.39K | ﹤0.01% | 6380 |
|
|
2015
Q4 | $76K | Buy |
126
+69
| +121% | +$46.7K | ﹤0.01% | 5600 |
|
|
2015
Q3 | $47K | Buy |
+57
| New | +$64.3K | ﹤0.01% | 5488 |
|
Other funds holding SRRA
Citigroup's SRRA Position: Q3 2022 in Review
Citigroup sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 280,324 shares — an estimated $15.4M sold.
Citigroup first reported a position in SRRA in Q3 2015 and held it in 19 quarters. The position peaked at $15.4M in Q2 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.
- Citigroup reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- Citigroup sold 280,324 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $15.4M.
- Citigroup first reported a position in Sierra Oncology, Inc. Common Stock in Q3 2015 and held it in 19 quarters.
- Citigroup's Sierra Oncology, Inc. Common Stock position peaked at $15.4M in Q2 2022.
- 1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.
Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.